Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company’s major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients.
Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anaemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS)associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.
(Wiki)
Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in…
Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful…
Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain…
When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain…
Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and…
Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty…
Celgene is a relative newcomer to China. What’s the story behind how the company entered the market, and how did you yourself come to manage the local operations? I officially…
“Australia is not just a postbox for selling drugs; Celgene is committed to establishing a major presence in the region,” you said when Focus Reports met you first in 2008.…
In our interviews we have been hearing two opinions on the success of PBS reforms: that it works as it should in providing space for innovative medicine listings, and that…
Ms. Polekova, you established the Celgene affiliate in this country from scratch in 2008. When we spoke to Mr. Victor Ferkovich, your colleague in Russia, he commented on his own…
What were the first challenges you have faced as the new General Manager of Celgene turkey? In all humility, I have to say that even though it is always challenging…
Celgene just announced very impressive second quarter results for its global operations, with a 38% increase in revenue partly led by strong growth in Europe. Within the global performance of…
The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What are your observations, and how do you expect companies…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
Could you please give our readers an overview of the importance of Taiwan for Celgene in a regional and a global context? What is attractive in Taiwan for Celgene? Celgene…
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Annie Tan highlights the strategy she laid out to navigate the BMS Singapore, Thailand and Malaysia affiliates through the COVID-19 pandemic; the opportunities and challenges of integrating the Celgene portfolio…
Dr Remo Gujer gives an overview of the BMS footprint in Switzerland and Austria, the ongoing integration of legacy Celgene operations, market access challenges, clinical trials, and the importance of…
With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an…
Stefan Larson, CEO of Northern Biologics, explains the major milestones for Northern Biologics over the past three years, his personal motivation for starting a biotech company, their collaboration with Celgene,…
Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in…
Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics…
Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help…
Celgene is committed to improving the lives of patients through innovation. The country manager of the recently opened Mexico affiliate explains the importance of having a direct presence in the…
Fermin Rivas Lopez, Country Manager of Celgene Portugal, gives his insight on Portugal’s recent economic problems, the challenges Celgene Portugal faces due to the economic state of the country, and…
Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty…
See our Cookie Privacy Policy Here
